Skip to main content

Table 3 Logistic regression of factors involved in the development of KTD

From: Clinical and genetic factors associated with kidney tubular dysfunction in a real-life single centre cohort of HIV-positive patients

  Bivariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
Female vs male 0,814 0,336 1974 0,650     
Caucasian vs Non-Caucasian 1883 0,304 11,684 0,497     
Baseline age (per yrs) 0,989 0,956 1023 0,524     
BMI ≤18 vs > 18 1133 0,335 3840 0,841     
TDF as part of first ARV regimen vs TDF as part of second or further ARV regimens 0,341 0,162 0,715 0,004 1040 0,195 5537 0,963
Previous therapy duration (per yrs) 1057 0,988 1131 0,110 0,948 0,854 1051 0,309
Baseline CD4 cell count (per cells/mL) 1000 0,999 1001 0,907     
Baseline Plasma HIV-RNA level (per log cps/mL) 0,793 0,677 0,929 0,004 0,809 0,578 1132 0,216
HCV coinfection 1444 0,505 4131 0,493     
Baseline creatinine (per mg/dL) 1999 0,138 28,861 0,611     
Duration of treatment with TDF (per months) 1006 0,998 1015 0,162 0,998 0,987 1009 0,672
Use of protease inhibitors 0,823 0,396 1712 0,602     
Hypertension 2039 0,769 5405 0,152 0,991 0,318 3084 0,987
Diabetes 2477 0,714 8595 0,153 3670 0,914 14,740 0,067
Bone diseasea 3178 1529 6603 0,002 3147 1361 7279 0,007
ABCC2–24 C > T (CC vs CT/TT) 0,689 0,332 1428 0,316     
ABCC4 3463 A > G (GG vs AG/AA) 4667 1247 17,464 0,022 2663 0,610 11,621 0,193
ABCC10 rs2125739 T > C (CC vs TC/TT) 0,530 0,111 2525 0,425     
  1. Abbreviations: OR odds ratio, CI confidence interval, cps copies, yrs. years, BMI body mass index, KTD kidney tubular dysfunction, ABCC ATP-binding cassette, ARV antiretroviral therapy; aosteopenia/osteoporosis; TDF tenofovir diproxil fumarate; p values are for χ2